

VITALS

Major Finding: Mean Kleiner scores were higher in patients with diabetes than in those who did not have diabetes (6.4 vs. 4.7; *P* less than .001).

Data Source: Retrospective study of 112 patients with biopsy-proven NAFLD linking severity of disease with the Framingham Risk Score and QRISK2; 32 had diabetes mellitus.

Disclosures: The study was funded by the National Institute for Health Research and Diabetes UK. Dr. Byrne and Ms. Hudson said they had no relevant financial disclosures. Dr. Byrne has given lectures on behalf of pharmaceutical companies in the past, including Pfizer.


concentration of highly purified omega-3 fatty acid ethyl esters to treat NAFLD.

The highly purified fish oil being used in the trial has been available commer-

cially in Europe for at least a decade (Omacor) and in the United States since 2004 (Lovaza), and is currently licensed to treat hypertriglyceridemia. ■

DATA WATCH

Black High School Students Consume More Soda, Sports, and Energy Drinks Than Do Whites, Hispanics



*Not including diet forms.

Note: Based on interviews with 11,429 students for the 2010 National Youth Physical Activity and Nutrition Study.

Source: MMWR 2011;60:778-80

ELSEVIER GLOBAL MEDICAL NEWS



Use in Specific Populations

- **Patients with Renal Impairment:** The dose of ONGLYZA is 2.5 mg once daily for patients with moderate or severe renal impairment, or with end-stage renal disease requiring hemodialysis (creatinine clearance [CrCl] \leq 50 mL/min). ONGLYZA should be administered following hemodialysis. ONGLYZA has not been studied in patients undergoing peritoneal dialysis. Assessment of renal function is recommended prior to initiation of ONGLYZA and periodically thereafter.
- **Pregnant and Nursing Women:** There are no adequate and well-controlled studies in pregnant women. ONGLYZA, like other antidiabetic medications, should be used during pregnancy only if clearly needed. It is not known whether saxagliptin is secreted in human milk. Because many drugs are secreted in human milk, caution should be exercised when ONGLYZA is administered to a nursing woman.
- **Pediatric Patients:** Safety and effectiveness of ONGLYZA in pediatric patients have not been established.

For more information about Onglyza, visit www.onglyza.com/three.

Please read the adjacent Brief Summary of the Product Information.

*Pioglitazone or rosiglitazone

†Based on Tier 2 coverage and the Onglyza Value Card Program.

See Onglyza Value Card Program details at www.onglyza.com/hcp/value-card.aspx.

Reference: 1. Fingertip Formulary® data as of March 18, 2011. Data on File, March 2011.



onglyza[™]
(saxagliptin) 5 mg tablets

 Bristol-Myers Squibb

AstraZeneca 